Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Sidney Reilly who wrote (4242)	12/5/2001 6:35:49 PM
From: Gary Mohilner	Read Replies (1) \| Respond to of 5665

It's up to GSK investors to start a thread if they wish. It seems like most GSK investors seem willing to sit back and wait for the company to tell them what's happening. They defend the company for not wanting to speak out about products like C242-DM1 until it's close to approval. I suppose if I were a company the size of GSK I'd be highlighting what's expected to happen in the next 6 months to a year as well. However, companies like GSK who make partnerships with companies like IMGN have to realize that investors at such companies are interested in everything that relates to a drug their company has provided. The problem is trying to satisfy investors from both companies. I believe Mitch does a good job of keeping us informed in a general way, but when we look for the specifics, he's prevented from giving them to us. I don't know that IMGN gets all the fine detail, but I do believe they have regular contact with the Doctors running the trials, and I believe they're well aware of how things are going. When Mitch speaks to a conference, or individual investor, the message has always been positive. He's spoken of New Paradigm's in treating cancer, he's let us know the dosage levels they are reaching, and he's mentioned anecdotal evidense of efficacy. What Mitch has not, and cannot do, is give us specifics, that's up to the doctors when they present at the appropriate forum, and it's also up to GSK to determine how much specific information they're willing to announce. The fact that GSK's investors aren't clamoring for Phase I Trial Data is probably the biggest reason the details given in the PR were so limited. It should be noted that Mitch was able to straighten out the confusion about what happened to the patient that had over 60% tumor reduction, although his explanation didn't get near the coverage of the initial PR. Gary